Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biotech Vaneck ETF (BBH)

Biotech Vaneck ETF (BBH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 509,801,300
  • Market Capitalization, $K 509,801
  • Shares Outstanding, K 3,047
  • 60-Month Beta 1.13
  • Price/Earnings ttm 22.86
  • Annual Dividend & Yield 0.47 (0.28%)
  • Most Recent Dividend 0.472 on 12/23/19
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
151.00 +11.32%
on 06/12/20
169.64 -0.91%
on 07/07/20
+9.35 (+5.89%)
since 06/08/20
3-Month
133.72 +25.71%
on 04/13/20
169.64 -0.91%
on 07/07/20
+33.16 (+24.57%)
since 04/08/20
52-Week
112.03 +50.05%
on 03/23/20
169.64 -0.91%
on 07/07/20
+40.96 (+32.22%)
since 07/08/19

Most Recent Stories

More News
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

JNJ : 143.27 (+0.29%)
AZN : 54.19 (+1.35%)
PFE : 33.75 (-0.82%)
MRNA : 61.58 (+0.80%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
FBT : 174.53 (+0.90%)
ARKG : 57.63 (+2.64%)
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

JNJ : 143.27 (+0.29%)
AZN : 54.19 (+1.35%)
MRNA : 61.58 (+0.80%)
IBB : 140.81 (+0.54%)
CNCR : 27.76 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
IDNA : 39.59 (+1.51%)
How Are Biotech ETFs Reacting to Coronavirus Treatment News?

Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.

GILD : 75.61 (-1.06%)
LLY : 169.13 (+1.43%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
FBT : 174.53 (+0.90%)
ARKG : 57.63 (+2.64%)
These ETF Areas Make Great Investment Choices in June

Here we highlight some ETF areas that will make interesting investment options for investors amid the coronavirus crisis.

IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
JETS : 16.33 (+0.18%)
IBUY : 77.16 (+2.23%)
BOTZ : 24.69 (+0.98%)
SKYY : 77.86 (+2.57%)
CLIX : 81.64 (+2.27%)
IRBO : 31.00 (+1.34%)
CLOU : 22.90 (+2.74%)
Biotech ETFs Soaring on COVID-19 Vaccine Progress

Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.

JNJ : 143.27 (+0.29%)
AZN : 54.19 (+1.35%)
MRNA : 61.58 (+0.80%)
NVAX : 98.30 (-5.99%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
FBT : 174.53 (+0.90%)
ARKG : 57.63 (+2.64%)
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.

JNJ : 143.27 (+0.29%)
SNY : 51.52 (+0.17%)
PFE : 33.75 (-0.82%)
MRK : 77.92 (-1.02%)
MRNA : 61.58 (+0.80%)
GSK : 40.73 (+0.87%)
NVAX : 98.30 (-5.99%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
BBC : 44.07 (+1.68%)
ARKG : 57.63 (+2.64%)
BNTX : 67.56 (-2.57%)
GNOM : 18.71 (+1.87%)
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

JNJ : 143.27 (+0.29%)
SNY : 51.52 (+0.17%)
AZN : 54.19 (+1.35%)
MRNA : 61.58 (+0.80%)
GSK : 40.73 (+0.87%)
NVAX : 98.30 (-5.99%)
IBB : 140.81 (+0.54%)
CNCR : 27.76 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
IDNA : 39.59 (+1.51%)
Moderna Soars: Biotech ETFs in Focus

Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.

JNJ : 143.27 (+0.29%)
PFE : 33.75 (-0.82%)
MRNA : 61.58 (+0.80%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

JNJ : 143.27 (+0.29%)
SNY : 51.52 (+0.17%)
PFE : 33.75 (-0.82%)
MRNA : 61.58 (+0.80%)
GSK : 40.73 (+0.87%)
NVAX : 98.30 (-5.99%)
EBS : 94.41 (+5.52%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
PTH : 129.29 (+1.28%)
DWAS : 55.16 (+1.21%)
Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

BIIB : 280.19 (+4.41%)
ALXN : 108.00 (-3.97%)
GILD : 75.61 (-1.06%)
AMGN : 251.59 (-0.62%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BBH with:

Fund Summary

The VanEck Vectors Biotech ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of...

See More

Key Turning Points

2nd Resistance Point 170.01
1st Resistance Point 169.06
Last Price 168.10
1st Support Level 166.87
2nd Support Level 165.63

See More

52-Week High 169.64
Last Price 168.10
Fibonacci 61.8% 147.63
Fibonacci 50% 140.83
Fibonacci 38.2% 134.04
52-Week Low 112.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar